Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: Waldenström’s Macroglobulinemia

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

VJHemOnc presents the Waldenström’s Macroglobulinemia Channel

Welcome to the Waldenström’s Macroglobulinemia Channel, bringing you the latest data from world-renowned experts on Waldenström’s macroglobulinemia through exclusive interviews, podcasts, roundtable discussions, and more.

Explore the latest advances, such as rituximab and proteasome inhibitor-based therapies that have demonstrated efficacy in symptom management, and targeted therapies that are increasingly playing a role in tailoring treatment options, directly from leading experts on the Waldenström’s Macroglobulinemia Channel.

An update on BTK-targeting therapies in NHL & CLL: combinations, BTK degraders, and ongoing trials 14:48
An update on BTK-targeting therapies in NHL & CLL: combinations, BTK degraders, and ongoing trials
Alexey Danilov et al. • 28 Sep 2025
Therapeutic goals in Waldenström’s macroglobulinemia: achieving disease control 1:06
Therapeutic goals in Waldenström’s macroglobulinemia: achieving disease control
Anna Maria Frustaci • 20 Jun 2025
The role of therapeutic plasma exchange in managing plasma cell disorders 7:59
The role of therapeutic plasma exchange in managing plasma cell disorders
Danai Dima • 24 Jun 2025
Updates from the BRAWM trial: bendamustine, rituximab and acalabrutinib in patients with WM 1:59
Updates from the BRAWM trial: bendamustine, rituximab and acalabrutinib in patients with WM
Neil Berinstein • 19 Jun 2025
Sonrotoclax monotherapy in R/R Waldenström’s macroglobulinemia: initiation of BGB-11417-203 0:51
Sonrotoclax monotherapy in R/R Waldenström’s macroglobulinemia: initiation of BGB-11417-203
Chan Yoon Cheah • 14 Jun 2025
The safety of bendamustine-rituximab and acalabrutinib in frontline Waldenström’s macroglobulinemia 1:25
The safety of bendamustine-rituximab and acalabrutinib in frontline Waldenström’s macroglobulinemia
Neil Berinstein • 19 Jun 2025
Emerging agents for Waldenström’s macroglobulinemia: non-covalent BTKis, BCL2 antagonists, & more 1:11
Emerging agents for Waldenström’s macroglobulinemia: non-covalent BTKis, BCL2 antagonists, & more
Neil Berinstein • 19 Jun 2025
Salvage treatment strategies after covalent BTKis in Waldenström’s macroglobulinemia 1:47
Salvage treatment strategies after covalent BTKis in Waldenström’s macroglobulinemia
Anna Maria Frustaci • 20 Jun 2025
Updated data on the safety and efficacy of BGB-16673 in R/R Waldenström’s macroglobulinemia 1:38
Updated data on the safety and efficacy of BGB-16673 in R/R Waldenström’s macroglobulinemia
Anna Maria Frustaci • 20 Jun 2025
The potential of translational research to impact the diagnosis & management of B-cell lymphomas 1:13
The potential of translational research to impact the diagnosis & management of B-cell lymphomas
Christian Buske • 14 Jun 2025
The epigenetics of MYD88 wild-type Waldenström’s macroglobulinemia 2:08
The epigenetics of MYD88 wild-type Waldenström’s macroglobulinemia
Karan Chohan • 18 Jun 2025
Long-term outcomes of patients with Waldenström’s macroglobulinemia who discontinue BTKi therapy 1:51
Long-term outcomes of patients with Waldenström’s macroglobulinemia who discontinue BTKi therapy
Karan Chohan • 18 Jun 2025
Novel treatment modalities emerging for WM: bispecifics, CAR T-cells & combinations with BTKis 1:13
Novel treatment modalities emerging for WM: bispecifics, CAR T-cells & combinations with BTKis
Steven Treon • 19 Jun 2025
The impact of TP53 mutations on the prognosis of patients with Waldenström’s macroglobulinemia 1:18
The impact of TP53 mutations on the prognosis of patients with Waldenström’s macroglobulinemia
Steven Treon • 19 Jun 2025
Exciting developments in Waldenström’s macroglobulinemia: insights from a ‘Meet the Expert’ session 2:56
Exciting developments in Waldenström’s macroglobulinemia: insights from a ‘Meet the Expert’ session
Steven Treon • 19 Jun 2025
Treatment approaches for symptomatic, treatment-naive WM versus previously treated patients 1:49
Treatment approaches for symptomatic, treatment-naive WM versus previously treated patients
Steven Treon • 19 Jun 2025

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Diamond Supporter

AstraZeneca

Gold Supporter

BMS Johnson & Johnson

Silver Supporter

Takeda

Bronze Supporter

Galapagos

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals